These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7398912)

  • 1. Polycystic ovarian disease associated with hyperprolactinemia and defective metoclopramide response.
    Alger M; Vazquez-Matute L; Mason M; Canales ES; Zárate A
    Fertil Steril; 1980 Jul; 34(1):70-1. PubMed ID: 7398912
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperprolactinemia and polycystic ovarian syndrome.
    Tzingounis VA; Aksu MF; Tsoukalos SG
    Int J Fertil; 1979; 24(4):276-80. PubMed ID: 45100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulating effect on the hypothalamo-hypophyseo-ovarian axis observed during the process of treating polycystic ovarian disease by tonifying the kidney and resolving phlegm].
    Yu J
    Zhong Xi Yi Jie He Za Zhi; 1986 Apr; 6(4):218-21, 195-6. PubMed ID: 2945659
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serum prolactin concentration after metoclopramide stimulation in patients with polycystic ovary syndrome].
    Baranowska B; Jeske W; Stopińska-Głuszak U
    Endokrynol Pol; 1983; 34(1):55-60. PubMed ID: 6347673
    [No Abstract]   [Full Text] [Related]  

  • 5. [Polycystic ovary syndrome with excess of prolactin].
    Ataniiazova OA; Orlova VG; Smetnik VP; Afonina LI
    Akush Ginekol (Mosk); 1990 Apr; (4):42-4. PubMed ID: 2143054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome.
    Vaitukaitis JL
    Compr Ther; 1986 Dec; 12(12):32-7. PubMed ID: 3791930
    [No Abstract]   [Full Text] [Related]  

  • 7. [Endocrinological environment in polycystic ovarian disease (PCOD)].
    Fujimoto S; Tanaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Sep; 40(9):1465-70. PubMed ID: 3049852
    [No Abstract]   [Full Text] [Related]  

  • 8. Basal and metoclopramide induced prolactin secretion in lean PCOS women.
    Mrozinska S; Przywara-Sikora A; Doroszewska K; Gałuszka-Bednarczyk A; Kiałka M; Guzik J; Janeczko M; Marianowski P; Dabrowski FA; Milewicz T
    Neuro Endocrinol Lett; 2019 Dec; 40(6):257-262. PubMed ID: 32200584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis.
    Szulc-Kuberska J; Stepień H; Klimek A; Cieślak D
    J Neurol Neurosurg Psychiatry; 1988 May; 51(5):643-5. PubMed ID: 3404163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome.
    Siegel SF; Lee PA
    Curr Opin Pediatr; 1993 Aug; 5(4):400-6. PubMed ID: 8374664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of therapeutic outcomes of polycystic ovary syndrome patients with hyperprolactinemia].
    Shi YH; Sheng Y; Chen ZJ; Yan JH; Gao Q; Liu H; Ma ZX
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):251-3. PubMed ID: 18843962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metoclopramide test in women with PCO syndrome after ovarian wedge resection.
    Vĕtr M; Talas M; Sobek A; Charamza J
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():257-64. PubMed ID: 1838876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome.
    Falaschi P; Rocco A; del Pozo E
    J Clin Endocrinol Metab; 1986 Feb; 62(2):348-51. PubMed ID: 3510225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists for polycystic ovary disease?
    González ER
    JAMA; 1982 Aug; 248(5):514. PubMed ID: 7097888
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.
    Lewinthal D; Corenblum B; Taylor PJ
    Int J Fertil; 1987; 32(3):185-7, 191. PubMed ID: 2885281
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma prolactin and dehydroepiandrosterone sulfate levels in polycystic ovarian disease.
    Lee JY; Yoon BK; Moon SY; Kim JG; Chang YS
    Asia Oceania J Obstet Gynaecol; 1987 Jun; 13(2):215-20. PubMed ID: 2957985
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of hyperprolactinemia-anovulation syndrome.
    Floersheim-Shachar Y; Keller PJ
    Fertil Steril; 1977 Nov; 28(11):1158-63. PubMed ID: 562780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin release in polycystic ovary.
    Falaschi P; del Pozo E; Rocco A; Toscano V; Petrangeli E; Pompei P; Frajese G
    Obstet Gynecol; 1980 May; 55(5):579-82. PubMed ID: 6768043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of bromocryptin in polycystic ovary syndrome].
    Fuhrer J; Cheviakoff S; Rubio V
    Rev Chil Obstet Ginecol; 1989; 54(6):364-9; discussion 369-70. PubMed ID: 2485372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.